Company profile for Aytu BioScience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "L...
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
373 Inverness Parkway, Suite 206 Englewood, CO 80112
Telephone
Telephone
+1 855-298-8246
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accesswire.com/639869/Aytu-BioPharma-Adds-Late-Stage-Pediatric-Onset-Rare-Disease-Asset-to-Development-Pipeline-from-Rumpus-Therapeutics

ACCESWIRE
13 Apr 2021

https://www.accesswire.com/638540/Aytu-BioPharma-Divests-US-Rights-to-NatestoR-to-Acerus-Pharma

ACCESSWIRE
01 Apr 2021

https://www.biospace.com/article/releases/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics/?s=79

BIOSPACE
22 Mar 2021

https://www.biospace.com/article/releases/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics/?s=79

BIOSPACE
22 Mar 2021

https://www.biospace.com/article/releases/aytu-bioscience-and-neos-therapeutics-announce-special-meetings-of-stockholders-related-to-proposed-merger-to-be-held-on-march-18-2021/?s=79

BIOSPACE
10 Feb 2021

https://www.biospace.com/article/releases/aytu-bioscience-announces-closing-of-28-75-million-bought-deal-offering-and-full-exercise-of-underwriter-s-option-to-purchase-additional-shares/#:~:text=(NASDAQ%3AAYTU)%2C%20(,Company%2C%20which%20includes%20the%20full

BIOSPACE
15 Dec 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty